Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-07-10. Part of the child ADHD research overview.
Short answer. ADHD medications fall into two broad classes. Stimulants — methylphenidate-based and amphetamine-based — are the most-studied and, on average, the most effective for reducing core ADHD symptoms; they act quickly (often within an hour) and wear off the same day. Non-stimulants — atomoxetine, and the alpha-agonists guanfacine and clonidine — work more gradually, take weeks to reach full effect, and provide steadier all-day coverage without the abuse potential of stimulants. The AAP guideline (Wolraich et al., 2019) names stimulants as first-line pharmacological treatment for school-aged children, with non-stimulants as options when stimulants are poorly tolerated, insufficiently effective, or contraindicated. Cortese et al.'s (2018) network meta-analysis in Lancet Psychiatry supported methylphenidate as the first-choice medication in children and adolescents on balance of efficacy and tolerability. This page is educational; drug selection and dosing are decisions only your child's clinician can make.
The clinical distinction that matters most to parents is how fast and how long each works, and why a clinician would reach for it.
| Stimulants | Non-stimulants | |
|---|---|---|
| Examples | Methylphenidate class; amphetamine class | Atomoxetine; guanfacine (ER); clonidine (ER) |
| Onset of effect | Fast — often within ~30–60 min of an effective dose | Gradual — days to several weeks for full effect |
| Duration | IR: a few hours; ER: most of a school day | Steady, all-day coverage once established |
| On/off pattern | Noticeable ramp-up and wear-off each day | Little day-to-day on/off; effect is continuous |
| Evidence base | Largest; generally highest average efficacy | Effective, generally more modest average effect |
| Abuse/diversion potential | Yes (controlled substances) | No |
| Typical role | First-line for most school-aged children (AAP) | When stimulants fail, aren't tolerated, or are contraindicated; sometimes as an add-on |
| Notable considerations | Appetite suppression, sleep-onset delay, rebound | Atomoxetine: slow ramp; alpha-agonists: sedation, blood-pressure effects |
The table is a map, not a prescription. Individual response varies widely, and a child who does poorly on one class or one specific medication may do well on another — the reason medication for ADHD is a titration process, not a one-shot decision.
Stimulants are the oldest and best-evidenced ADHD medications. They come in two families — methylphenidate-based and amphetamine-based — each available in immediate-release (a few hours of effect) and extended-release (most of a school day) formulations. Their defining features are speed and a clear daily shape: an effective dose typically produces a noticeable change within about an hour, and the effect wears off the same day, which is why timing, boosters, and rebound are recurring themes in stimulant management.
Because stimulants have the largest average effect on core symptoms, the AAP guideline (Wolraich et al., 2019) makes them first-line for children aged 6 and older, alongside behavioural parent training. Cortese et al. (2018), pooling 133 trials, concluded that on the combined balance of efficacy and tolerability, methylphenidate was the first-choice stimulant in children and adolescents (amphetamines carried the first-choice signal in adults). Trade-offs — appetite suppression, delayed sleep onset, late-day rebound irritability — track the drug's pharmacokinetics and are covered in more depth under is the medication helping? and medication or behaviour?.
Non-stimulants are the alternative when stimulants don't fit. Two sub-types matter:
The AAP and AACAP frameworks position non-stimulants as second-line for most children — real, evidence-based options with generally more modest average effect sizes than stimulants, reached for when stimulants are insufficiently effective, poorly tolerated, or contraindicated. "Second-line" is not "inferior for your child": the child who cannot tolerate stimulant side effects may do far better on a non-stimulant.
The choice between and within classes is individualised. Clinicians weigh the child's age, symptom profile, co-occurring conditions (tics, anxiety, sleep problems), family preference and history, side-effect tolerance, and abuse/diversion risk in the household. The AAP's process is explicitly a titration: start, measure response and side effects with structured ratings, and adjust — often trying a second agent if the first is a poor fit. Because response is idiosyncratic, "stimulant vs non-stimulant" is rarely settled in the abstract; it is settled by a monitored trial.
For parents, the useful preparation is the same as for any medication review: bring structured weekly data on benefit and side effects, and one specific question. If the current medication isn't fitting, when to switch medications walks through the signals that justify raising a change with the prescriber. Nothing here is a dosing recommendation — the class, agent, and dose are clinical decisions.
---
Unseen Progress publishes long-form caregiver research. See the full child ADHD research overview for the complete framework.